Among HBsAg-negative/anti-HBc–positive diffuse large B-cell lymphoma (DLBCL) patients treated with R-CHOP, 25% (5/21) developed HBV reactivation; none had HBV reactivation in patients treated with CHOP [13]. Here, KRT88P is linked to diffuse large B-cell lymphoma.